Deutsche Bank’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-383
| Closed | -$5.66K | – | 3770 |
|
|
2024
Q1 | $5.66K | Sell |
383
-596
| -61% | -$8.37K | ﹤0.01% | 3557 |
|
|
2023
Q4 | $13.1K | Buy |
979
+69
| +8% | +$872 | ﹤0.01% | 3522 |
|
|
2023
Q3 | $11.2K | Buy |
+910
| New | +$11K | ﹤0.01% | 3552 |
|
|
2020
Q2 | – | Sell |
-1,103
| Closed | -$2K | – | 4650 |
|
|
2020
Q1 | $2K | Sell |
1,103
-20,028
| -95% | -$58.6K | ﹤0.01% | 4237 |
|
|
2019
Q4 | $65K | Sell |
21,131
-4,491
| -18% | -$18K | ﹤0.01% | 3830 |
|
|
2019
Q3 | $114K | Sell |
25,622
-7,198
| -22% | -$36K | ﹤0.01% | 3493 |
|
|
2019
Q2 | $155K | Sell |
32,820
-4,733
| -13% | -$22.4K | ﹤0.01% | 3981 |
|
|
2019
Q1 | $204K | Buy |
37,553
+2,034
| +6% | +$9.35K | ﹤0.01% | 3989 |
|
|
2018
Q4 | $107K | Sell |
35,519
-3,178
| -8% | -$11K | ﹤0.01% | 4196 |
|
|
2018
Q3 | $163K | Buy |
38,697
+8,265
| +27% | +$34.8K | ﹤0.01% | 4321 |
|
|
2018
Q2 | $117K | Sell |
30,432
-303,461
| -91% | -$2.01M | ﹤0.01% | 4496 |
|
|
2018
Q1 | $2.11M | Buy |
333,893
+151,161
| +83% | +$1.25M | ﹤0.01% | 2823 |
|
|
2017
Q4 | $1.47M | Sell |
182,732
-19,165
| -9% | -$179K | ﹤0.01% | 2945 |
|
|
2017
Q3 | $2.31M | Buy |
201,897
+34,441
| +21% | +$362K | ﹤0.01% | 2443 |
|
|
2017
Q2 | $1.63M | Buy |
167,456
+18,882
| +13% | +$386K | ﹤0.01% | 2692 |
|
|
2017
Q1 | $3.6M | Sell |
148,574
-26,672
| -15% | -$667K | ﹤0.01% | 1877 |
|
|
2016
Q4 | $5.62M | Sell |
175,246
-11,707
| -6% | -$499K | ﹤0.01% | 1598 |
|
|
2016
Q3 | $9.34M | Sell |
186,953
-9,213
| -5% | -$382K | 0.01% | 1355 |
|
|
2016
Q2 | $8.32M | Sell |
196,166
-35,107
| -15% | -$1.91M | 0.01% | 1416 |
|
|
2016
Q1 | $15.2M | Buy |
231,273
+8,250
| +4% | +$431K | 0.01% | 1028 |
|
|
2015
Q4 | $13.9M | Sell |
223,023
-1,841
| -0.8% | -$130K | 0.01% | 1129 |
|
|
2015
Q3 | $15.1M | Sell |
224,864
-5,504
| -2% | -$449K | 0.01% | 1055 |
|
|
2015
Q2 | $22.4M | Buy |
230,368
+3,043
| +1% | +$290K | 0.01% | 877 |
|
|
2015
Q1 | $21.2M | Sell |
227,325
-19,069
| -8% | -$1.62M | 0.01% | 900 |
|
|
2014
Q4 | $21.9M | Buy |
246,394
+6,144
| +3% | +$448K | 0.01% | 963 |
|
|
2014
Q3 | $16.6M | Sell |
240,250
-69,369
| -22% | -$3.71M | 0.01% | 1039 |
|
|
2014
Q2 | $17.8M | Buy |
309,619
+211,292
| +215% | +$10.7M | 0.01% | 1013 |
|
|
2014
Q1 | $3.9M | Buy |
98,327
+8,901
| +10% | +$381K | ﹤0.01% | 1995 |
|
|
2013
Q4 | $3.75M | Sell |
89,426
-10,008
| -10% | -$290K | ﹤0.01% | 1938 |
|
|
2013
Q3 | $2.96M | Buy |
99,434
+80,716
| +431% | +$2.82M | ﹤0.01% | 2205 |
|
|
2013
Q2 | $992K | Buy |
+18,718
| New | +$820K | ﹤0.01% | 2705 |
|
Other funds holding MACK
RA
JC
Deutsche Bank's MACK Position: Q2 2024 in Review
Deutsche Bank sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 383 shares — an estimated $5.66K sold.
Deutsche Bank first reported a position in MACK in Q2 2013 and held it in 31 quarters. The position peaked at $22.4M in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Deutsche Bank reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Deutsche Bank sold 383 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $5.66K.
- Deutsche Bank first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 31 quarters.
- Deutsche Bank's Merrimack Pharmaceuticals, Inc. position peaked at $22.4M in Q2 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Deutsche Bank's 13F filing for Q2 2024, filed 14 Aug 2024.